| Bioactivity | C1A is a class I/II HDACs and sirtuin inhibitor with an IC50 of 479 nM for HDAC6. C1A induces sustained acetylation of HDAC6 substrates, α-tubulin and HSP90. C1A shows srtong anticancer effcts, and induces apoptosis in cancer cells[1]. |
| Invitro | C1A (0.5-10 μM; 4-24 h) induces sustained acetylation of HDAC6 substrates, α-tubulin and HSP90[1]. C1A（2.5-10 μM；24 小时）以药物浓度相关的方式增加亚 G1 群体。C1A 在低微摩尔范围内诱导细胞凋亡并抑制来自不同来源的一组人类肿瘤细胞系的增殖[1]。C1A（0.5-10 μM；4-24 小时）诱导 HDAC6 底物、α-微管蛋白和 HSP90 的持续乙酰化[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> C1A 相关抗体: Cell Cycle Analysis[1] Cell Line: |
| In Vivo | C1A（40 mg/kg；腹腔注射；每天一次、每天两次、每两天一次；持续 14 天）抑制体内结肠肿瘤的生长[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1021463-02-4 |
| Formula | C22H25Cl2N3O4S |
| Molar Mass | 498.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. M Kaliszczak, et al. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. Br J Cancer. 2013 Feb 5;108(2):342-50. |